List view / Grid view
10 September 2014 | By Actavis
Actavis plc confirmed that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension...
10 September 2014 | By DPT Laboratories
DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities...
8 September 2014 | By Mundipharma
New data from a randomised, multicentre, phase III study, being presented at the European Respiratory Society (ERS) annual congress in Munich, Germany, supports the potential of flutiform® for the treatment of paediatric asthma...
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
8 September 2014 | By AstraZeneca
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress...
8 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU...
8 September 2014 | By Abbott
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million)...
8 September 2014 | By GlaxoSmithKline
GSK presented data at the European Respiratory Society Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid containing regimen...
5 September 2014 | By Merck
Merck announced that the U.S. Food and Drug Administration has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimuma...
5 September 2014 | By Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States...
5 September 2014 | By Abbott
Abbott announced that it has received CE Mark for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes...
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
4 September 2014 | By Andrew Lloyd & Associates
Nosopharm announces its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance...
4 September 2014 | By Roche
Roche announced that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico...
4 September 2014 | By Masters
Masters Speciality Pharma signs agreement for the exclusive distribution of Ferriprox® (deferiprone)...
